Patents by Inventor Alejandro Santillan, Jr.

Alejandro Santillan, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
    Publication number: 20090099158
    Abstract: Certain substituted tetrahydroisoquinoline compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.
    Type: Application
    Filed: February 28, 2008
    Publication date: April 16, 2009
    Inventors: Cheryl A. Grice, Michael A. Letavic, Alejandro Santillan, JR., Kimberly L. Schwarz
  • Aryl piperidine amides
    Patent number: 7276610
    Abstract: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: October 2, 2007
    Assignee: Janssen Pharaceutica, NV
    Inventors: Charles Q. Huang, Timothy W. Lovenberg, Alejandro Santillán, Jr., Liu Y. Tang, Ronald L. Wolin
  • GlyT2 modulators
    Patent number: 7202269
    Abstract: Certain ?-, ?-, and ?-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: April 10, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tristin K. Barclay, Alejandro Santillán, Jr., Liu Y. Tang, Hariharan Venkatesan, Ronald L. Wolin